Flunarizine in the Prevention of Classical Migraine: A Placebo-Controlled Evaluation

Abstract

Pharmacological data and early clinical experience have suggested that the calcium entry blocker flunarizine may be a valuable asset in the prophylaxis of migraine. This was supported by a study in twenty patients with classical migraine who were, after a drug-free running-in phase, orally treated with either placebo or flunarizine (10 mg at night) for three to four months. Flunarizine significantly reduced the frequency, duration and severity of the migraine attacks. A corrected migraine index, based on these three variables, was reduced by 82% in the drug group but increased by 66% in the control patients. Only one patient did not clearly benefit from flunarizine, and the response in another illustrated that flunarizine has to be given for at least four months before its efficacy can be judged in some cases. No side effects occurred.

Keywords

Calcium entry blocker classical migraine flunarizine migraine prophylaxis

Get full access to this article

View all access options for this article.

References

Verhaegen

Roels

Adriaensen

Brugmans

De Cock

Dony

Jageneau

Schuermans

. The arteriolar effects of cinnarizine and flunarizine. Multitechnical investigations in normal volunteers and in patients with occlusive disease of the extremities, secondary to arteriosclerosis. Angiology 1974;25:261–78.

Staessen

. Treatment of circulatory disturbances with flunarizine and cinnarizine. A multicenter double-blind and placebo-controlled evaluation. VASA 1977;6:59–71.

Domschky

Nelson

Dammhayn

Terjung

. Flunarizine in patients with insufficient cerebral and peripheral blood flow. Med Welt 1977;28:1062–4.

Roekaerts

Morias

Platteau

Mertens

RLJ

Peremans

. The efficacy of flunarizine in venous insufficiency: a double-blind placebo-controlled study. Curr Ther Res 1979;26:363–71.

Wouters

Amery

Towse

. Flunarizine in the treatment of vertigo. J Laryngol Otol 1983;97:697–704.

Van Nueten

Van Beek

Janssen

JAJ

. Effect of flunarizine on calcium-induced responses of peripheral vascular smooth muscle. Arch Int Pharmacodyn Ther 1978;232:42–52.

Wauquier

Ashton

Clincke

Van Reempts

. Pharmacological protection against brain hypoxia: the efficacy of flunarizine, a calcium entry blocker. In; Clifford-Rose

Amery

W K

eds The role of hypoxia in the pathogenesis of migraine. London: Pitman, 1982:139–54.

Amery . The anti-migrainous pharmacology of flunarizine (R 14 950) a calcium antagonist. Drugs Exp Clin Res 1981;7:1–10.

Amery

. An epilogue: cerebral hypoxia and migraine. In: Clifford-Rose

Amery

eds The role of hypoxia in the pathogenesis of migraine. London: Pitman, 1982:195–200.

10.

Drillisch

Girke

. Results of the treatment of migraine patients with cinnarizine and flunarizine. Med Welt 1980;31:1870–2.

11.

Louis

. A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium^R) in migraine. Headache 1981;21:235–9.

12.

Amery

. Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Headache 1983;23:70–4.

13.

Diamond

Schenbaum

. Flunarizine, a calcium channel blocker, in the prophylactic treatment of migraine. Headache 1983;23:39–42.

14.

Ad Hoc Committee on Classification of Headache of the NIH. JAMA 1962;179:717–8.